cagrilintide + semaglutide New in the August 14, 2025, issue of NEJM: Cagrilintide–Semaglutide for Overweight or Obesity (REDEFINE 1 phase 3a trial) Cagrilintide– for Overweight and Diabetes (REDEFINE 2 phase 3a trial) Cagrilintide Semaglutide
Description
Semaglutide is an FDA-approved medication designed to combat obesity and loss weight
Partly through these actions, GLP-1 receptor agonism was shown to reduce cardiovascular disease (CVD) in people with T2D with previous CVD or at high-risk thereof
Rajat Goel are helping people lose weight without going under the knife
Early-stage research suggests drugs like Ozempic, Wegovy, Zepbound, and Mounjaro can lower the odds of developing certain cancers
Methods We conducted a systematic review of studies from PubMed, Embase, and Cochrane databases (until November 2024), as well as relevant abstracts from Digestive Disease Week (DDW) 2024 and American College of Gastroenterology (ACG) 2024 to assess the impact of GLP-1 receptor agonists (GLP-1 RAs) on EGD
Can I use Wegovy®
